$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000114420417009000 Filed on February 14, 2017

Income Statement

Concept	2016 Q4	2016 Q2	2015 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.040M	$890.0K	$940.0K
YoY Change	10.64%	-15.24%	18.99%
% of Gross Profit
Research & Development	$1.261M	$1.600M	$1.153M
YoY Change	9.41%	15.11%	25.72%
% of Gross Profit
Depreciation & Amortization	$162.4K	$160.0K	$163.9K
YoY Change	-0.88%	14.29%	219.26%
% of Gross Profit
Operating Expenses	$2.298M	$2.500M	$2.090M
YoY Change	9.92%	2.46%	22.68%
Operating Profit	-$2.298M		-$2.090M
YoY Change	9.92%		22.68%
Interest Expense	$245.0K	$1.230M	$245.0K
YoY Change	0.0%	-32.79%	-0.99%
% of Operating Profit
Other Income/Expense, Net	$751.2K	-$380.0K	-$685.0K
YoY Change	-209.67%	22.58%	286.48%
Pretax Income	-$1.546M	-$1.650M	-$2.775M
YoY Change	-44.28%	79.35%	47.53%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.546M	-$1.650M	-$2.775M
YoY Change	-44.28%	79.35%	47.53%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03		-$0.05
Diluted Earnings Per Share	-$0.03	-$569.0K	-$0.05
COMMON SHARES
Basic Shares Outstanding	58.21M shares		57.59M shares
Diluted Shares Outstanding	58.21M shares		57.59M shares

Balance Sheet

Concept	2016 Q4	2016 Q2	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.30M	$24.16M	$28.24M
YoY Change	-31.66%	-23.23%	-19.91%
Cash & Equivalents	$19.30M	$24.16M	$28.24M
Short-Term Investments
Other Short-Term Assets	$140.0K	$220.0K	$110.0K
YoY Change	27.27%		-54.17%
Inventory
Prepaid Expenses	$139.7K	$219.5K	$106.0K
Receivables
Other Receivables
Total Short-Term Assets	$19.44M	$24.38M	$28.34M
YoY Change	-31.41%	-23.04%	-20.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.46M	$11.76M	$12.00M
YoY Change	-4.51%	-1.69%	12.05%
Goodwill
YoY Change
Intangibles	$387.3K	$391.5K	$395.6K
YoY Change	-2.09%	-2.07%
Long-Term Investments
YoY Change
Other Assets	$80.00K	$100.0K	$110.0K
YoY Change	-27.27%	-28.57%	-89.0%
Total Long-Term Assets	$11.92M	$12.25M	$12.51M
YoY Change	-4.69%	-2.02%	3.18%
TOTAL ASSETS
Total Short-Term Assets	$19.44M	$24.38M	$28.34M
Total Long-Term Assets	$11.92M	$12.25M	$12.51M
Total Assets	$31.36M	$36.63M	$40.85M
YoY Change	-23.23%	-17.09%	-14.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$160.0K	$860.0K	$1.290M
YoY Change	-87.6%	109.76%	81.69%
Accrued Expenses	$51.59K	$35.60K	$12.60K
YoY Change	309.57%	24.85%	-92.13%
Deferred Revenue
YoY Change
Short-Term Debt	$5.910M	$5.470M	$0.00
YoY Change
Long-Term Debt Due	$5.911M	$5.475M
YoY Change
Total Short-Term Liabilities	$6.320M	$6.744M	$1.467M
YoY Change	330.93%	1022.33%	30.95%
LONG-TERM LIABILITIES
Long-Term Debt	$3.520M	$3.130M	$7.860M
YoY Change	-55.22%		19.63%
Other Long-Term Liabilities	$2.380M	$3.710M	$3.130M
YoY Change	-23.96%	-19.7%	-66.74%
Total Long-Term Liabilities	$5.902M	$6.841M	$11.00M
YoY Change	-46.33%	-42.03%	-31.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.320M	$6.744M	$1.467M
Total Long-Term Liabilities	$5.902M	$6.841M	$11.00M
Total Liabilities	$12.22M	$13.59M	$12.46M
YoY Change	-1.98%	9.55%	-27.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$69.43M	-$64.82M	-$58.18M
YoY Change	19.34%	19.82%
Common Stock		$58.18K	$57.82K
YoY Change		1.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.15M	$23.05M	$28.38M
YoY Change
Total Liabilities & Shareholders Equity	$31.36M	$36.63M	$40.85M
YoY Change	-23.22%	-17.09%	-14.2%

Cashflow Statement

Concept	2016 Q4	2016 Q2	2015 Q4
OPERATING ACTIVITIES
Net Income	-$1.546M	-$1.650M	-$2.775M
YoY Change	-44.28%	79.35%	47.53%
Depreciation, Depletion And Amortization	$162.4K	$160.0K	$163.9K
YoY Change	-0.88%	14.29%	219.26%
Cash From Operating Activities	-$2.620M	-$1.380M	-$1.220M
YoY Change	114.75%	10.4%	4.27%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$60.00K	-$30.00K
YoY Change	-100.0%	-95.0%	-99.37%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities	$0.00	-$60.00K	-$30.00K
YoY Change	-100.0%	-95.0%	-99.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-2.620M	-1.380M	-1.220M
Cash From Investing Activities	0.000	-60.00K	-30.00K
Cash From Financing Activities		0.000	0.000
Net Change In Cash	-2.620M	-1.440M	-1.250M
YoY Change	109.6%	-41.22%	-78.67%
FREE CASH FLOW
Cash From Operating Activities	-$2.620M	-$1.380M	-$1.220M
Capital Expenditures	$0.00	-$60.00K	-$30.00K
Free Cash Flow	-$2.620M	-$1.320M	-$1.190M
YoY Change	120.17%	2540.0%	-133.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	58179	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	24381643	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64824201	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	23048214	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36633418	USD
CY2016Q2	us-gaap	Liabilities Liabilities	13585204	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51590	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35602	USD
CY2016Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	32624	USD
CY2016Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	96524	USD
CY2016Q2	us-gaap	Assets Assets	36633418	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19301566	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24162185	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	387333	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	391467	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	71621	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	67487	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2016Q2	nnvc	Service Agreements ServiceAgreements	96026	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11459482	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11760767	USD
CY2016Q4	nnvc	Service Agreements ServiceAgreements	72651	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	139721	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2176536	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69432044	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1850816	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13636018	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13611583	USD
CY2016Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	219458	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	19441287	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	126059	USD
CY2016Q4	us-gaap	Liabilities Liabilities	12218250	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	19146018	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2297618	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2090301	USD
CY2016Q4	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	423287	USD
CY2015Q4	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	349962	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	337194	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1546400	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2775292	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
CY2015Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2016Q2	us-gaap	Security Deposit SecurityDeposit	3515	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31364268	USD
CY2016Q4	us-gaap	Security Deposit SecurityDeposit	3515	USD
CY2016Q4	us-gaap	Other Assets OtherAssets	76166	USD
CY2016Q2	us-gaap	Other Assets OtherAssets	99541	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5910835	USD
CY2016Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	5474737	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	28284	USD
CY2016Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	203030	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2016Q2	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2016Q4	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	83333	USD
CY2016Q2	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	166667	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5902191	USD
CY2016Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6841190	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88515497	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87810145	USD
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1261000	USD
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1036618	USD
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	937800	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	2297618	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	2090301	USD
CY2016Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11734	USD
CY2015Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4562	USD
CY2016Q4	us-gaap	Interest Expense InterestExpense	245000	USD
CY2015Q4	us-gaap	Interest Expense InterestExpense	245000	USD
CY2016Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1407771	USD
CY2015Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-85467	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	751218	USD
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-684991	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1546400	USD
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2775292	USD
CY2016Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-1546400	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-2775292	USD
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58205494	shares
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57588081	shares
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58205494	shares
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57588081	shares
	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	355335	USD
	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	54000	USD
	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	27145	USD
	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	22500	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	79799	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	76500	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3230127	USD
	us-gaap	Interest Paid InterestPaid	490000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4135	USD
	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	313	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24435	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	363486	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	27145	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	16976	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	355335	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Depreciation Depreciation	325720	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	683670	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	15987	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-15919	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-83333	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2866641	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4836184	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31467748	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28237621	USD
	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-83334	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4082246	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1421062	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-79737	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	29535	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	86655	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-33388	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-734830	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	794974	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-23375	USD
	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6010971	shares
CY2016Q4	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q4	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.03
CY2015Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1546400	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2775292	USD
CY2016Q4	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015Q4	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2016Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2016Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2016Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2016Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	46897	USD
CY2016Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2016Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5302677	USD
CY2016Q4	us-gaap	Land Land	260000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	58069	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	75000	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58458989	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58458989	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58179699	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58179699	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2713137	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2359573	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2024930	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1955779	USD
	us-gaap	Operating Expenses OperatingExpenses	4738067	USD
	us-gaap	Operating Expenses OperatingExpenses	4315352	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	826749	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	683670	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1421062	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1402515	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	130224	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	233106	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4607843	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4082246	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4738067	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4315352	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25911	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4261	USD
	us-gaap	Interest Expense InterestExpense	490000	USD
	us-gaap	Interest Expense InterestExpense	490000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58192721	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57431198	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58192721	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57431198	shares
	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	246667	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-246667	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-246667	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2016Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	23804	USD
CY2016Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9997	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	27145	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4607843	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4082246	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.08
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4607843	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4082246	USD
	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
CY2016Q4	us-gaap	Depreciation Depreciation	162433	USD
CY2015Q4	us-gaap	Depreciation Depreciation	163880	USD
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc.
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
	nnvc	Depreciation Due To Decommissioning Of Fixed Assets DepreciationDueToDecommissioningOfFixedAssets	0	USD
	nnvc	Depreciation Due To Decommissioning Of Fixed Assets DepreciationDueToDecommissioningOfFixedAssets	332476	USD
	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the “Redemption Warrants”, and collectively with (i) (iv), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Note 1 - Organization and Nature of Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">NanoViricides, Inc. was incorporated under the laws of the State of Colorado on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> July 25, 2000</font> as <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Edot-com.com, Inc.</font> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s Common Stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECMM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. Under the License Agreements, TheraCour Pharma will receive a royalty upon sale of resulting products from NanoViricides. There is no royalty payable to date. For further details, see Note 4.  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”). The Series A Preferred Stock is convertible, only in the event of a “change of control” of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The 2,000,000 shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001144204-17-009000-index-headers.html	Edgar Link	pending
0001144204-17-009000-index.html	Edgar Link	pending
0001144204-17-009000.txt	Edgar Link	pending
0001144204-17-009000-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20161231.xml	Edgar Link	completed
nnvc-20161231.xsd	Edgar Link	pending
nnvc-20161231_cal.xml	Edgar Link	unprocessable
nnvc-20161231_def.xml	Edgar Link	unprocessable
nnvc-20161231_lab.xml	Edgar Link	unprocessable
nnvc-20161231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v458345_10q.htm	Edgar Link	pending
v458345_ex31-1.htm	Edgar Link	pending
v458345_ex31-2.htm	Edgar Link	pending
v458345_ex32-1.htm	Edgar Link	pending
v458345_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2016 Q4 Form 10-Q Financial Statement

#000114420417009000 Filed on February 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2016 Q4 Form 10-Q Financial Statement

#000114420417009000 Filed on February 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc